Statins lower cholesterol by blocking an enzyme your liver needs to produce it. When the liver can no longer make enough cholesterol on its own, it compensates by pulling more LDL (the “bad” cholesterol) out of your bloodstream. This two-step process, reducing production and increasing clearance, is what makes statins the most widely prescribed cholesterol-lowering drugs in the world.
How Statins Block Cholesterol Production
Your liver manufactures most of the cholesterol in your body through a multi-step chemical assembly line called the mevalonate pathway. Early in that process, an enzyme converts a raw material into a building block that eventually becomes cholesterol. Statins are shaped almost identically to that raw material, so they slip into the enzyme’s active site and block it, like jamming a wrong key into a lock. The enzyme can’t do its job, and cholesterol production slows down.
This blocking action happens primarily in the liver rather than throughout the body. After you swallow a statin, the liver absorbs most of the drug on its first pass through, which keeps circulating drug levels low and concentrates the effect where it matters most. The liver is responsible for the bulk of your body’s cholesterol output, so targeting it specifically is what gives statins their potency.
Why Less Production Means Less LDL in Your Blood
The drop in liver cholesterol production triggers a chain reaction that’s just as important as the initial block. When liver cells sense that their internal cholesterol supply is running low, they activate a protein called SREBP-2, a kind of molecular alarm switch. This protein ramps up the production of LDL receptors on the surface of liver cells. Think of these receptors as tiny docking stations: the more of them there are, the more LDL particles the liver can grab from the bloodstream and absorb.
So statins work on two fronts simultaneously. They reduce how much new cholesterol the liver makes, and they force the liver to scavenge more LDL from your blood to compensate. The net result is a significant drop in circulating LDL cholesterol.
How Much LDL Drops and How Quickly
Statins are grouped into three intensity levels based on how aggressively they lower LDL. High-intensity therapy reduces LDL by 50% or more. Moderate-intensity therapy brings it down 30% to 50%. Low-intensity therapy lowers it by less than 30%. Your prescribed intensity depends on your overall cardiovascular risk, not just your cholesterol number.
Results come faster than most people expect. You can see measurable changes in LDL levels within four weeks of starting a statin. By one to three months, the improvement is noticeable, and at the three-month mark you’re seeing more or less the full effect regardless of which statin you’re taking. This is why doctors typically recheck your lipid panel about three months after you start or change a dose.
Benefits Beyond Cholesterol Reduction
Statins do more than just lower a number on a lab report. They improve the function of blood vessel walls by boosting nitric oxide, a molecule that keeps arteries relaxed and flexible. They reduce inflammation throughout the cardiovascular system. In clinical trials, statins lowered a key marker of inflammation (high-sensitivity CRP) by 20% to 28% in just six weeks, independent of their effect on LDL.
Perhaps most importantly for people who already have plaque buildup, statins help stabilize those plaques. Unstable plaques are the ones that rupture and cause heart attacks. By calming inflammation within the plaque and strengthening its outer shell, statins reduce the chance of a sudden cardiovascular event even before they’ve had time to significantly shrink the plaque itself.
Muscle Symptoms and Other Side Effects
Muscle aches are the side effect people worry about most, and roughly 10% of statin users report some degree of muscle symptoms. Here’s what’s reassuring: more than 80% of those cases turn out not to be caused by the statin itself. When researchers test this with blinded trials, where patients don’t know whether they’re taking the real drug or a placebo, most people experience the same symptoms on both.
For those who do have genuine statin-related muscle discomfort, switching to a different statin or lowering the dose usually solves the problem. About 60% to 80% of people who initially report muscle symptoms are eventually able to tolerate some statin regimen.
One real risk worth knowing about: high-intensity statin therapy is associated with a 36% relative increase in new diabetes diagnoses compared to placebo, based on a large meta-analysis published in The Lancet. In absolute terms, this translates to a small number of additional cases, and for most people the cardiovascular benefit far outweighs this risk. But if you’re already borderline for diabetes, it’s something your doctor may factor into choosing your dose.
Drug Interactions to Watch For
Not all statins are processed by the body the same way. Simvastatin and atorvastatin are broken down by a specific liver enzyme (CYP3A4), which means any other medication that competes for that same enzyme can cause statin levels to build up in your blood. Higher statin levels increase the risk of muscle damage. Common culprits include certain antibiotics (erythromycin, clarithromycin), antifungal medications, and some HIV drugs. If you need a short course of one of these medications, your doctor may temporarily pause your statin.
Other statins, like pravastatin and rosuvastatin, largely bypass this enzyme pathway and are less prone to these interactions. Pravastatin in particular is excreted mostly unchanged and carries minimal interaction risk. This is one reason doctors sometimes choose a specific statin based on your other medications rather than just its cholesterol-lowering power.
How Risk Level Shapes Treatment Goals
The 2026 ACC/AHA guidelines use a 10-year cardiovascular risk score to determine how aggressively cholesterol should be treated. For adults aged 30 to 79 without existing heart disease, risk falls into four categories based on the estimated chance of a heart attack or stroke in the next decade.
- Low risk (under 3%): Lifestyle changes like diet and exercise are typically the first approach, with a focus on keeping LDL below 160 mg/dL.
- Borderline risk (3% to 5%): If a statin is started, moderate intensity is reasonable, with an LDL goal under 100 mg/dL.
- Intermediate risk (5% to 10%): At least a moderate-intensity statin is recommended, with high intensity considered for those at the upper end. The LDL target is under 100 mg/dL.
- High risk (10% or above): High-intensity statin therapy is recommended to cut LDL by at least 50%, aiming for an LDL goal below 70 mg/dL.
For people with very high baseline LDL (190 mg/dL or above), a statin alone may not be enough to reach target levels. Additional medications that work through different mechanisms can be added to close the gap.